Want to see USAQ full AI Analyst Report?
USAQ Stock Chart & Stats
$0.32
$0.05(16.00%)
At close: 4:00 PM EDT
$0.32
$0.05(16.00%)
Day’s Range― - ―
52-Week Range$0.08 - $1.14
Previous CloseN/A
Volume1.06K
Average Volume (3M)3.01K
Market Cap
$5.26M
Enterprise Value$5.89
Total Cash (Recent Filing)$317.39K
Total Debt (Recent Filing)$95.55K
Price to Earnings (P/E)7.4
Beta1.32
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding15,032,788
10 Day Avg. Volume3,305
30 Day Avg. Volume3,010
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.21
Price to Sales (P/S)2.54
P/FCF Ratio38.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring ISP Platform GrowthThe shift toward a recurring, software-enabled healthcare platform can improve revenue visibility and deepen provider relationships. Rapid ISP growth and increasing revenue mix support a more scalable business model if adoption continues.
Revenue And Gross-margin ExpansionSustained revenue expansion alongside a high and improving gross margin indicates stronger product economics and operating leverage. This provides a foundation for future profitability as QHSLab scales its digital medicine and integrated services.
Repaired Balance Sheet And Lower Interest BurdenVery low leverage and restored positive equity materially reduce solvency risk and improve financial flexibility. Retirement of legacy convertible debt also lowers interest drag, allowing more operating resources to support product development and growth.
Bears Say
Negative Operating And Free Cash FlowNegative cash conversion despite reported net income weakens earnings quality and limits internally funded growth. If working-capital swings or higher cash costs persist, QHSLab may need tighter spending controls or external capital to maintain expansion.
Operating Profitability Remains InconsistentThe improving earnings profile has not yet demonstrated stable operating profitability across periods. Margin volatility makes it harder to assess normalized earnings power and raises the risk that current profitability may not persist through changing costs or demand.
Balance-sheet Recovery Has A Volatile HistoryThe repaired capital structure is a clear improvement, but prior negative equity shows that financial resilience has not been proven through a long operating history. Elevated recent returns may also overstate sustainable performance during the recovery phase.
QHSLab News
USAQ FAQ
What was QHSLab’s price range in the past 12 months?
QHSLab lowest stock price was $0.08 and its highest was $1.14 in the past 12 months.
What is QHSLab’s market cap?
QHSLab’s market cap is $5.26M.
When is QHSLab’s upcoming earnings report date?
QHSLab’s upcoming earnings report date is Apr 01, 2027 which is in 209 days.
How were QHSLab’s earnings last quarter?
QHSLab released its earnings results on Aug 03, 2026. The company reported $0.002 earnings per share for the quarter.
Is QHSLab overvalued?
According to Wall Street analysts QHSLab’s price is currently Overvalued.
Does QHSLab pay dividends?
QHSLab does not currently pay dividends.
What is QHSLab’s EPS estimate?
QHSLab’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does QHSLab have?
QHSLab has 15,032,788 shares outstanding.
What happened to QHSLab’s price movement after its last earnings report?
QHSLab reported an EPS of $0.002 in its last earnings report. Following the earnings report the stock price went up 57.94%.
Which hedge fund is a major shareholder of QHSLab?
Currently, no hedge funds are holding shares in USAQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
QHSLab
QHSLab, Inc. is a company operating in the medical technology and Software-as-a-Service (SaaS) sectors. Its core focus is on advancing value-based healthcare, medical informatics, and personalized medicine driven by algorithms. The firm also develops digital therapeutic solutions and on-site technologies intended for remote patient oversight, the management of chronic conditions, and proactive health maintenance. Among its offerings is a proprietary cloud-based SaaS platform, also known as QHSLab (Quality Health Score Lab expert system). This system empowers physicians and healthcare organizations to securely record and store electronic patient data. Additionally, QHSLab, Inc. acts as a distributor, providing primary care physicians with AllergiEnd, a product line encompassing diagnostic tools and allergen immunotherapy treatments. All of its solutions are strategically designed to aid in the prevention, early identification, effective management, and potential reversal of chronic diseases. The company was established in 1983 and is headquartered in West Palm Beach, Florida. It operated under the name USA Equities Corp. until April 2022, when it officially rebranded to QHSLab, Inc. The company also maintains a strategic partnership with Medical License Factory, LLC.